A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
A phase 3 trial of Ripretinib and Sunitinib in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.
Overview
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib is a phase 3 interventional study registered as NCT03673501 by Deciphera Pharmaceuticals, LLC, with 453 participants enrolled, started 2019-02-08 and due to reach its primary completion in 2021-09-01. Interventions recorded: Ripretinib and Sunitinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Shares Deciphera Pharmaceuticals (Ono), Gastrointestinal stromal tumour (GIST) and the tag pipeline.
- TrialA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Shares Ripretinib, Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Sunitinib and the tag pipeline.